Patient-Oriented Perspective on Chemokine Receptor Expression and Function in Glioma

Damla Isci; Giulia D'Uonnolo; May Wantz; Bernard Rogister; Arnaud Lombard; Andy Chevigné; Martyna Szpakowska; Virginie Neirinckx

doi:10.3390/cancers14010130

Patient-Oriented Perspective on Chemokine Receptor Expression and Function in Glioma

Cancers (Basel). 2021 Dec 28;14(1):130. doi: 10.3390/cancers14010130.

Authors

Damla Isci¹, Giulia D'Uonnolo^{2

3}, May Wantz², Bernard Rogister^{1

4}, Arnaud Lombard^{1

5}, Andy Chevigné², Martyna Szpakowska^{2

6}, Virginie Neirinckx¹

Affiliations

¹ Laboratory of Nervous System Diseases and Therapy, GIGA Neuroscience, GIGA Institute, University of Liège, 4000 Liege, Belgium.
² Immuno-Pharmacology and Interactomics, Department of Infection and Immunity, Luxembourg Institute of Health, 1445 Strassen, Luxembourg.
³ Faculty of Science, Technology and Medicine, University of Luxembourg, 4365 Esch-sur-Alzette, Luxembourg.
⁴ Neurology Department, University Hospital, University of Liège, 4000 Liege, Belgium.
⁵ Neurosurgery Department, University Hospital, University of Liège, 4000 Liege, Belgium.
⁶ Tumor Immunotherapy and Microenvironment, Department of Oncology, Luxembourg Institute of Health, 1445 Strassen, Luxembourg.

Abstract

Gliomas are severe brain malignancies, with glioblastoma (GBM) being the most aggressive one. Despite continuous efforts for improvement of existing therapies, overall survival remains poor. Over the last years, the implication of chemokines and their receptors in GBM development and progression has become more evident. Recently, large amounts of clinical data have been made available, prompting us to investigate chemokine receptors in GBM from a still-unexplored patient-oriented perspective. This study aims to highlight and discuss the involvement of chemokine receptors-CCR1, CCR5, CCR6, CCR10, CX3CR1, CXCR2, CXCR4, ACKR1, ACKR2, and ACKR3-most abundantly expressed in glioma patients based on the analysis of publicly available clinical datasets. Given the strong intratumoral heterogeneity characterizing gliomas and especially GBM, receptor expression was investigated by glioma molecular groups, by brain region distribution, emphasizing tissue-specific receptor functions, and by cell type enrichment. Our study constitutes a clinically relevant and patient-oriented guide that recapitulates the expression profile and the complex roles of chemokine receptors within the highly diversified glioma landscape. Additionally, it strengthens the importance of patient-derived material for development and precise amelioration of chemokine receptor-targeting therapies.

Keywords: chemokine receptor; glioma; malignant processes; patient-derived transcriptomic data; tumor microenvironment.

Publication types

Review

Abstract

Publication types

Grants and funding